EGFR+ Lung Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they interpret the ADAURA trial and the approach to adjuvant targeted therapy in non–small cell lung cancer This is the second of two articles based on this event.

In an interview with Targeted Oncology, Jonathan W. Riess, MD, discussed the ever-changing EGFR-mutated lung cancer treatment landscape, highlighting several agents that are currently under development.

During a Targeted Oncology™ Case-Based Roundtable™ event, Balazs Halmos, MD, discussed with participants how they would approach the case of a patient with T3N0 lung adenocarcinoma of stage IIB. This is the first of 2 articles based on this event.

The FDA is considering 2 applications for amivantamab plus lazertinib as a first-line treatment for EGFR-mutated non–small cell lung cancer, based on the phase 3 MARIPOSA study.

Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.

Telisotuzumab vedotin demonstrated promising efficacy and safety in patients with advanced nonsquamous non–small cell lung cancer with high or intermediate c-Met expression.

Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.

Julia Rotow, MD, discussed emerging data on upfront therapies for patients with lung cancer harboring EGFR mutations in a presentation at the 18th Annual New York Lung Cancers Symposium.

Amivantamab-vmjw with lazertinib showed positive survival results vs osimertinib as frontline therapy for patients with advanced non–small cell lung cancer harboring classical EGFR sensitizing mutations.

In the VISION trial, tepotinib led to clinically meaningful results in treatment-naïve and pretreated patients with METex14-skipping non–small cell lung cancer, supporting the use of MET inhibitors for this patient population.

In a live virtual event, Yasir Y. Elamin, MD, discussed biomarker testing and management of non–small cell lung cancer (NSCLC) and a related patient case with participating physicians.

A first-in-human trial is assessing the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of STX-721 as a monotherapy for patients with non–small cell lung cancer with EGFR exon 20 insertion mutations.

The FDA and Takeda have decided to voluntarily withdraw mobocertinib, a drug for patients with EGFR exon20 insertion mutation-positive non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, discussed subgroup analysis and safety of osimertinib based on the FLAURA trial. This is the second of 2 articles based on this event.

Data from a subgroup of patients with EGFR-mutated non–small cell lung cancer showed that an experimental treatment strategy using durvalumab and chemotherapy is not beneficial for patients.

Following PACIFIC-R trial, the ongoing phase 3 LAURA trial is working to evaluate the efficacy and safety of maintenance osimertinib for patients who have unresectable stage III, EGFR-mutated non–small cell lung cancer.

According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non–small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial.

Patritumab deruxtecan showed clinically meaningful and durable efficacy in the phase 2 HERTHENA-Lung01 trial of patients with advanced EGFR-mutated non–small cell lung cancer.

The phase 3 MARIPOSA-2 study has met its primary end point.

Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.

Based on positive phase 3 PAPILLON results, an application for a new approval for amivantamab has been filed with the FDA.

During a Targeted Oncology™ Case-Based Roundtable™ event, Martin F. Dietrich, MD, PhD, discussed the phase 2 data for osimertinib plus chemotherapy in EGFR-mutated non–small cell lung cancer and what they suggest for the upcoming phase 3 FLAURA2 trial results.

Determining the safety and efficacy of zipalertinib combined with chemotherapy for patients with EGFR exon 20 insertion mutation-positive non–small cell lung cancer are the key goals of the newly-launched phase 3 REZILIENT3 study.

PAPILLON represents the first randomized study of newly-diagnosed patients with EGFR exon 20-mutant non–small cell lung cancer to show clinically meaningful results.

The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor.

The most effective regimen has yet to be determined for patients with EGFR-mutated non–small cell lung cancer after progression on an EGFR-tyrosine kinase inhibitor. But chemotherapy regimens remain standard.

In an interview with Targeted Oncology, Nicholas Girard, MD, PhD reviews 3 key abstracts presented at the ELCC 2023, in which different targeted therapies were administered to patients with EGFR-mutant non–small cell lung cancer in clinical trial and real-world settings.

In an interview with Targeted Oncology, Benjamin Besse, MD, PhD, discussed recently reported results from the phase 1/1b CHRYSALIS-2 of amivantamab and lazertinib in patients with EGFR-mutated non–small cell lung cancer.